Image: Cambiotics
Cambiotics, a Copenhagen-based biotech company, has raised approximately €4 million in seed funding to develop a dietary supplement designed to remove PFAS – commonly known as “forever chemicals” – from the human body. The round was led by Collaborative Fund with participation from EIFO (Danish Export and Investment Fund) and True. BioInnovation Institute will convert approximately €2 million into equity as part of the round.
The funding will support Cambiotics’ first human clinical trial in the United States and preparation for the US launch of its product, 46&, later this year. Initial market focus will be on firefighters and other groups with elevated PFAS exposure, as well as the biohacker and health-optimization community.
PFAS are persistent environmental contaminants found in the blood of populations worldwide and linked to a range of adverse health outcomes. The company’s approach is based on research from the MRC Toxicology Unit at the University of Cambridge identifying gut bacteria capable of bioaccumulating PFAS and supporting their natural excretion from the body.
“The partnership with Collaborative Fund, EIFO, and True that this funding represents also marks the next phase of Cambiotics development, where focus will be on upscaling of products, clinical validation, and first launch of product in the US market,” said Peter Holme Jensen, CEO of Cambiotics.
Matt Kaufman, investor at Collaborative Fund, said: “PFAS exposure is a massive and growing problem. These chemicals are everywhere; they stay in the body for years, and nearly everyone already carries a measurable burden. Cambiotics is one of the first companies building a real path to removing PFAS from the body.”
Cambiotics was founded in 2024 as a spin-off from the University of Cambridge.
